Medtech Research Development News Today

Johnson & Johnson (NYSE: JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) through an exchange offer. Kenvue, formerly Johnson & Johnson’s Consumer Health business, completed its initial public offering (“IPO”) in May 2023. Through the planned ...

Separation enhances Company focus on Pharmaceutical and MedTech Research & Development to deliver innovative and differentiated health outcomes Johnson & Johnson shareholders can exchange all, some or none of